A beta Amyloid Pathology Affects the Hearts of Patients With Alzheimer%26apos;s Disease

作者:Troncone Luca; Luciani Marco; Coggins Matthew; Wilker Elissa H; Ho Cheng Ying; Codispoti Kari Elise; Frosch Matthew P; Kayed Rakez; del Monte Federica
来源:Journal of the American College of Cardiology, 2016, 68(22): 2395-2407.
DOI:10.1016/j.jacc.2016.08.073

摘要

BACKGROUND Individually, heart failure (HF) and Alzheimer's disease (AD) are severe threats to population health, and their potential coexistence is an alarming prospect. In addition to sharing analogous epidemiological and genetic profiles, biochemical characteristics, and common triggers, the authors recently recognized common molecular and pathological features between the 2 conditions. Whereas cognitive impairment has been linked to HF through perfusion defects, angiopathy, and inflammation, whether patients with AD present with myocardial dysfunction, and if the 2 conditions bear a common pathogenesis as neglected siblings are unknown. OBJECTIVES Here, the authors investigated whether amyloid beta (A beta) protein aggregates are present in the hearts of patients with a primary diagnosis of AD, affecting myocardial function. METHODS The authors examined myocardial function in a retrospective cross-sectional study from a cohort of AD patients and age-matched controls. Imaging and proteomics approaches were used to identify and quantify A beta deposits in AD heart and brain specimens compared with controls. Cell shortening and calcium transients were measured on isolated adult cardiomyocytes. RESULTS Echocardiographic measurements of myocardial function suggest that patients with AD present with an anticipated diastolic dysfunction. As in the brain, A beta(40) and A beta(42) are present in the heart, and their expression is increased in AD. CONCLUSIONS Here, the authors provide the first report of the presence of compromised myocardial function and intramyocardial deposits of A beta in AD patients. The findings depict a novel biological framework in which AD may be viewed either as a systemic disease or as a metastatic disorder leading to heart, and possibly multiorgan failure. AD and HF are both debilitating and life-threatening conditions, affecting enormous patient populations. Our findings underline a previously dismissed problem of a magnitude that will require new diagnostic approaches and treatments for brain and heart disease, and their combination.

  • 出版日期2016-12-6